Abstract
Cannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest thanks to its medical applications. This compound showed efficacy as anti-seizure, antipsychotic, neuroprotective, antidepressant and anxiolytic. The neuroprotective activity appears linked to its excellent anti-inflammatory and antioxidant properties. The purpose of this paper is to evaluate the use of CBD, in addition to common anti-epileptic drugs, in the severe treatment-resistant epilepsy through an overview of recent literature and clinical trials aimed to study the effects of the CBD treatment in different forms of epilepsy. The results of scientific studies obtained so far the use of CBD in clinical applications could represent hope for patients who are resistant to all conventional anti-epileptic drugs.
Highlights
Cannabis sativa L. is an ancient medicinal plant wherefrom over 100 cannabinoids are extracted [1].Cannabis sativa L. is an ancient medicinal plant wherefrom over 100 cannabinoids are extractedAmong them, the most studied are ∆9 –tetrahydrocannabinol (∆9 –THC), a9 psychoactive compound,[1]
The data obtained from this study show that CBD as an adjunct treatment to common anti-epileptic drugs (AEDs) can be used in the long-term effective treatment in patients with Treatment-Resistant Epilepsy (TRE)
The CBD is a compound extensively studied for its potential efficacy for the treatment of epilepsy
Summary
Cannabis sativa L. is an ancient medicinal plant wherefrom over 100 cannabinoids are extracted [1].Cannabis sativa L. is an ancient medicinal plant wherefrom over 100 cannabinoids are extractedAmong them, the most studied are ∆9 –tetrahydrocannabinol (∆9 –THC), a9 psychoactive compound,[1]. The most studied are Δ –tetrahydrocannabinol (Δ –THC), a psychoactive and the CBD, a non-psychotropic phytocannabinoid [2]. CBD is a cyclohexene which is substituted compound, and the CBD, a non-psychotropic phytocannabinoid [2]. CBD is a cyclohexene which is in position 1 by a methyl group, by a 2,6-dihydroxy-4-pentylphenyl group at position 3, and with substituted in position 1 by a methyl group, by a 2,6-dihydroxy-4-pentylphenyl group at position 3, a prop-1-en-2-yl group at position 4 (Figure 1). Most cannabinoids exert their action by interacting and with a prop-1-en-2-yl group at position 4 (Figure 1). It interacting with cannabinoid receptors, but CBD shows a low affinity for these receptors
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
